Sanofi Consumer Healthcare India Ltd
₹ 4,671
-0.58%
15 Oct
- close price
- Market Cap ₹ 10,718 Cr.
- Current Price ₹ 4,671
- High / Low ₹ 5,954 / 4,360
- Stock P/E 54.2
- Book Value ₹ 112
- Dividend Yield 1.18 %
- ROCE 111 %
- ROE 83.8 %
- Face Value ₹ 10.0
Pros
- Promoter holding has increased by 10.9% over last quarter.
Cons
- Stock is trading at 41.9 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Dec 2023 8m | Dec 2024 | TTM | |
---|---|---|---|
555 | 724 | 724 | |
337 | 454 | 465 | |
Operating Profit | 219 | 271 | 259 |
OPM % | 39% | 37% | 36% |
2 | -15 | 22 | |
Interest | 0 | 4 | 5 |
Depreciation | 2 | 4 | 8 |
Profit before tax | 219 | 247 | 270 |
Tax % | 25% | 27% | |
165 | 181 | 200 | |
EPS in Rs | 78.59 | 86.85 | |
Dividend Payout % | 6% | 70% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -5% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -12% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | -3% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 84% |
Balance Sheet
Figures in Rs. Crores
Dec 2023 | Dec 2024 | Jun 2025 | |
---|---|---|---|
Equity Capital | 2 | 23 | 23 |
Reserves | 206 | 250 | 234 |
0 | 20 | 28 | |
138 | 138 | 137 | |
Total Liabilities | 345 | 431 | 422 |
5 | 29 | 42 | |
CWIP | 3 | 1 | 0 |
Investments | 0 | 0 | 0 |
338 | 402 | 380 | |
Total Assets | 345 | 431 | 422 |
Cash Flows
Figures in Rs. Crores
Dec 2023 | Dec 2024 | |
---|---|---|
-0 | 439 | |
0 | 2 | |
2 | -116 | |
Net Cash Flow | 2 | 325 |
Ratios
Figures in Rs. Crores
Dec 2023 | Dec 2024 | |
---|---|---|
Debtor Days | 21 | 7 |
Inventory Days | 232 | 80 |
Days Payable | 144 | 138 |
Cash Conversion Cycle | 109 | -51 |
Working Capital Days | 134 | -33 |
ROCE % | 111% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
10 Oct - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2025 is enclosed.
-
Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)
10 Oct - CFO Narahari Naidu resigns; last working day 15 October 2025.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
30 Sep - Copies of Postal Ballot Notice of the Company published on 30th September 2025 in Business Standard and Sakal
-
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
29 Sep - Postal ballot seeking approval for Rs165m (OHIPL) and Rs900m (Opella SAS); e-voting 30 Sep–29 Oct 2025.
-
Closure of Trading Window
27 Sep - Trading window closed from 1 Oct 2025 until 48 hours after results for quarter/nine months ended 30 Sep 2025.
Business Overview:[1][2]
SCHIL was formed following its demerger from Sanofi India Limited, to establish a standalone Consumer Healthcare (CHC) business. It operates in the Consumer Healthcare (CHC) sector, providing self-care solutions across various health categories including allergy relief, pain management, and wellness